AbbVie Inc. (ABBV) EBITDA Margin: 28.82%
Is AbbVie Inc.’s EBITDA margin high or low?
AbbVie Inc.'s EBITDA margin of 28.82% is 13% below its 5-year average of 33.01%, near the low end of its 5-year range (26.47%–42.59%).
The EBITDA margin for AbbVie Inc. (ABBV) is 28.82% as of Wednesday, June 10, 2026. It is above its 12-month average by 4.25% (27.64%).
ABBV EBITDA Margin Chart
ABBV Average EBITDA Margin Chart
ABBV Current vs Average EBITDA Margin Chart
ABBV EBITDA Margin Metrics
EBITDA MARGIN
28.82%
EBITDA MARGIN AVG TTM
27.64%
EBITDA MARGIN AVG 3Y
32.13%
EBITDA MARGIN AVG 5Y
33.01%
EBITDA MARGIN AVG 10Y
33.84%
EBITDA MARGIN AVG 15Y
33.11%
EBITDA MARGIN AVG 20Y
33.56%
CURRENT VS TTM AVG
+4.25%
CURRENT VS 3Y AVG
-10.32%
CURRENT VS 5Y AVG
-12.68%
CURRENT VS 10Y AVG
-14.84%
CURRENT VS 15Y AVG
-12.96%
CURRENT VS 20Y AVG
-14.13%
ABBV Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | $399.54B | 28.82% | 27.64% | 32.13% | 33.01% |
| UnitedHealth Group Incorporated (UNH) | $368.44B | 5.15% | 6.08% | 7.94% | 8.50% |
| Merck & Co., Inc. (MRK) | $293.02B | 45.17% | 42.62% | 33.17% | 32.32% |
| Johnson & Johnson (JNJ) | $574.15B | 43.59% | 35.75% | 33.03% | 32.51% |
| Amgen Inc. (AMGN) | $183.75B | 43.12% | 41.54% | 45.45% | 46.07% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 25.73% | 26.63% | 26.49% | 27.97% |
| Abbott Laboratories (ABT) | $154.66B | 26.06% | 25.95% | 26.39% | 26.63% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 46.12% | 30.77% | 33.17% | 31.82% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 35.99% | 34.83% | 32.83% | 33.18% |
| Pfizer Inc. (PFE) | $146.36B | 24.12% | 26.30% | 27.39% | 29.84% |
Margin Comparison
Gross Margin
70.7%
EBITDA Margin
28.8%
Operating Margin
27.6%
Net Margin
5.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
AbbVie Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AbbVie Inc. EBITDA Margin FAQ
- What is the EBITDA margin for AbbVie Inc. (ABBV)?
- The EBITDA margin for ABBV stock is 28.82%.
- Is AbbVie Inc.'s EBITDA margin high or low?
- AbbVie Inc.'s EBITDA margin of 28.82% is 13% below its 5-year average of 33.01%, near the low end of its 5-year range (26.47%–42.59%).
- What is the TTM average EBITDA margin for AbbVie Inc. (ABBV)?
- The TTM average EBITDA margin for ABBV stock is 27.64%.
- What is the 3Y average EBITDA margin for AbbVie Inc. (ABBV)?
- The 3Y average EBITDA margin for ABBV stock is 32.13%.
- What is the 5Y average EBITDA margin for AbbVie Inc. (ABBV)?
- The 5Y average EBITDA margin for ABBV stock is 33.01%.
- What is the 10Y average EBITDA margin for AbbVie Inc. (ABBV)?
- The 10Y average EBITDA margin for ABBV stock is 33.84%.
- What is the 15Y average EBITDA margin for AbbVie Inc. (ABBV)?
- The 15Y average EBITDA margin for ABBV stock is 33.11%.
- What is the 20Y average EBITDA margin for AbbVie Inc. (ABBV)?
- The 20Y average EBITDA margin for ABBV stock is 33.56%.
AbbVie Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 28.82% |
| 2024-12-31 | 26.47% |
| 2023-12-31 | 31.61% |
| 2022-12-31 | 41.64% |
| 2021-12-31 | 42.59% |
| 2020-12-31 | 26.90% |
| 2019-12-31 | 36.76% |
| 2018-12-31 | 25.37% |
| 2017-12-31 | 36.78% |
| 2016-12-31 | 39.47% |
| 2015-12-31 | 35.87% |
| 2014-12-31 | 17.96% |
| 2013-12-31 | 34.74% |
| 2012-12-31 | 37.97% |
| 2011-12-31 | 28.32% |
| 2010-12-31 | 38.50% |
| 2009-12-31 | 40.80% |
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael